COX-2 Pipeline Drugs Will Need Additional Cardiovascular Data, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
COX-2 inhibitors in the R&D pipeline will need additional cardiovascular safety data prior to approval under FDA's risk management program for the drug class